IL6 and Erythema: The inhibition of LL37 could be a mechanism how both drugs improve the clinical features of rosacea such as erythema, telangiectasia and inflammation, since in a mouse model a LL37 injection led to such clinical features possibly through the enhanced expression of IL1, IL6 and MMP9 in mast cells42,43.